金投网

Delivery may disappoint

  中国金茂(00817)   What's new   China Jinmao released its 10M16 sales: we expect it toachieve sales of Rmb40bn (incl. primary land sales) in FY16.   Comments   Delivery of results falls behind performance ofcontracted sales (FY15: YoY +40%; FY16e: +30%) as:   FY16: core NP estimated to grow ~10% YoY, while core EPS(basic) only +2% YoY as it is diluted by larger share base.   FY17~18: we believe the growth rate will flatten to ~20%over the next two years, a common KPI for SOE managementto state in share option agreements.FY17e contracted sales: Rmb50bn, steady progress towardsits target of Rmb80bn (incl. primary land sales) by FY19.   Estimated growth of new starts +30~40% YoY in FY17 couldgive sufficient back-up.   Watch for any slowdown in the primary land markets of tier-1and core tier-2 cities �C such as Nanjing �C which are beingmore strictly managed & supervised by local governments.   Margins: new parcels coming in to give more pressure.YTD average land cost per GFA (newly acquired) could be aslarge as ~90% of 10M16’s ASP, although those parcels are alllocated in hot cities, such as Shanghai, Shenzhen, Nanjing, etc.   Defensive valuations. The company now trades at a 52%discount to 2016e NAV vs. the sector average of 46%.   Valuation and recommendation   We trim FY16e/17e core NP by 18%/12% toHK$3.14bn/3.82bn on slow delivery. Maintain BUY ratingbut cut TP by 14.5% to HK$2.59 (10.4x 2016e P/E),implying 26% upside and 40% discount to 2016e NAV. Thecompany currently trades at 8.1x 2016e P/E.   Risks   Delivery is better than expected.
免责声明 金投网发布此信息目的在于传播更多信息,与本网站立场无关。金投网不保证该信息(包括但不限于文字、数据及图表)全部或者部分内容的准确性、真实性、完整性、有效性、及时性、原创性等。相关信息并未经过本网站证实,不对您构成任何投资建议,据此操作,风险自担。
代码 名称 最新价(港元) 涨幅
01862 景瑞控股 0.14 238.1
00708 恒大健康 0.38 53.23
01396 毅德国际 0.75 47.06
02329 国瑞置业 0.08 46.15
08161 医汇集团 0.43 43.33

港股频道HKSTOCK.CNGOLD.ORG